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Chemical Agents and the Immune
Response
by Michael 1. Luster and Gary J. Rosenthal'
Ourdesiretounderstandthepotentialadversehumanhealtheffectsofenvironmentalchemical exposurehascoincid-
edwith anincreased understanding oftheimmune systemand anappreciationofitscomplexregulatorynetwork. This
hasspawned abroadinterestinthe areaofimmunotoxicologywithinthescientificcommunity aswell ascertain concerns
inthepublic sectorregardingchemical-inducedhypersensitivity and immunosuppon. Theincidenceofalleged human
sensitizationtochemicalshasincreased, inpart,duetothefactthatchemical companies aremovingtolargerand/ordif-
ferent markets. Ithasbeenestimatedthat35millionAmericanssufferfromallergic disease, ofwhich2-5% arefrom oc-
cupational exposure. Althoughthereis notyetaclearunderstanding ofdose-response relationships ordisease predisposi-
tion, there are manywell-definedexamples(isocyanates, anhydrides) ofchemicalsensitizersinhumansandexperimen-
talanimals. Evidencethatchemicals suppress immune responsesinhumansisconsiderably lesswellestablished, although
thereis apublic perceptionthatchemicals generally causeimmunosuppre'ion. This perceptionhasbeenfueledbyhighly
publicizedlegal casesandscientificcontroversies withintheacademicandindustrialcommunities. Asaconsequenceof
thesepublicandscientific concerns, manyoftheregulatory agencies aredevelopingimmunotoxicity testingguidelines.
Atthe present, however, there arelimitations onadequatehumanmethodology anddatathatallowtheextrapolationof
animal datato assesshuman risk. The potential forhumanimmunosuppression remainsofconcern, however, because
ofalargedatabasegeneratedfrom animalstudiesthatdemonstratesimmunosuppressionaswellasreportsofimmunosup-
pression inhumans inadvertently (e.g., halogenated aromatic hydrocarbons) oroccupationally (asbestos, benzene) ex-
posed to xenobiotics. This concern is exacerbated by currentknowledge regrding the long-term consequences ofim-
munosuppression that may be associated with pathologic conditions (e.g., cancer, increasedinfections). Likewise, exposure
to immunotoxic xenobiotics may represent additional risk to individuals with already fragile immune systems (e.g.,
malnutrition, infincy, oldage).Inanotherlight,therehasbeenconsiderablepublic concernregarding "chemicalhypersen-
sitivity syndrome" (alsoreferred to as"multiplechemicalsensitivities syndrome") anditsreationshiptohypersensitivity
as well asimmunosuppression. Although there exists asubstantial population whoclaim tohave thisdisorder, the syn-
drome is not well understood. Several mediators have been proposed includingdisorders ofimmune regulation as well
asconditioned responsestoodors involvingpharnacologicand/orpsychologicmechanisms. Atpresent, thereis nodefinitive
evidence that thesesyndromes are immunologically mediated.
Introduction
UnderDavidRall'sleadershipandinspiration, theNationalIn-
stituteofEnvironmental HealthSciences(NIEHS) was oneofthe
first institutions to initiate major research in the area of im-
munotoxicology. Since itsinception, NIEHShasmaintainedin-
ternational prominence inthis areathrough extramural funding,
sponsorship in numerous programs and conferences, and
through active supportofintramural research. Itis aprivilege to
contribute tothis specialEHPvolume inhonor ofDavid Rall's
retirement asDirectorofNIEHS. Inthis paper, webriefly review
some ofthe present issues confronting immunotoxicology and
describe recent research results from our laboratory.
As evidenced by recentdocuments preparedby the Officeof
Technology Assessment(1) andthe National Research Council
(2) focusing on immunotoxicology, there has beengrowing in-
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terestandconcernwithinthescientificandpubliccommunities
onthecapacityofcertainchemicalagentstoperturbnormal im-
mune processes. The types ofeffects shown to occur are often
chemical-specific as well as species-specific and include im-
munosuppression, targeting either systemic or local immunity
(e.g., lung or skin), hypersensitivity disease, manifested as
respiratory tractallergiesorcontactdermatitis, andincertainin-
stancesautoimmunity. Inaddition toenvironmental pollutants,
agentsofconcernhaveincludedcertaintherapeutics, consumer
products, andbiologicals(e.g., thetherapeutic useofrecombi-
nantmaterials). Morerecently, interesthasalsofocusedonsuch
diversematerialsassiliconeimplantsandpollutantscommonto
theindoorenvironment. Thelatterincludebothchemical agents
andbioaerosols suchasviruses, bacteria, fungi, algae, andpro-
tozoathathavethepotentialtoactaseithersensitizing agentsor
mediators ofinfectious disease.
Systemic Immunity
Anissuethatremainscontroversialinimmunotoxicology, and
islikelytoremainsointhenearfuture,isthequestionofwhether
chemical agents can suppress the immune response within theLUSTERANDROSENTHAL
general populationand, ifso, ifthiscanresultinclinicaldisease.
Suchdiseases would mostlikely bemanifested asanincreasein
thefrequency orseverityofinfectionsand increased incidences
ofcertain cancers such as Kaposi's sarcoma or non-Hodgkin's
lymphoma, malignanciesoftenobservedinimmunosuppressed
individuals. This concern is fueledby anumberofclinical and
experimental observations. First, although the association be-
tweenprimary immunodeficiency diseases andtheincidenceof
recurrent infections and neoplastic diseases is wellrecognized,
asimilar association tothesediseaseshasbeenrecognizedwith
the chronic low-level use of immunosuppressive agents (3),
which presumably inducemoderate levels ofimmunosuppres-
sion. Forexample, in one study, 30% ofcardiac transplant pa-
tients treatedwithcyclosporindevelopedpulmonary infections
withinthe firstyearaftersurgery (4), whereas inanotherstudy,
50% ofrenaltransplant patients on immunosuppressive therapy
were found todevelop cancer within 10yearsaftersurgery (5).
Second, there is an increasing number ofreports describing
various immune changes in individuals who have been in-
advertently oroccupationally exposed tochemical agents. These
range from unconfirmed reports withputativecompounds such
astrichloroethylene andmethyl isocyanatetomoresubstantiated
studies with polychlorinated biphenyls (PCBs), asbestos, and
silica(2). Asmaybeexpected, itisconsiderably moredifficult
toidentify subtlechanges inimmunefunctionafterinadvertent
or occupational exposure compared to the severe immune
dysfunctionthatoccursinHIVinfectionorprimaryimmunodefi-
ciency diseases. Severaldifficulties encountered includealack
ofsensitiveassaysthatusuallyaccompany routineclinical assess-
ment, problems in identifying recently exposed, well-defined
cohorts, andconsiderableimmunologicvariabilitythatexistsin
the general population.
Thethirdobservation, whichhasfueledinterestinchemical-
inducedimmunosuppression, stemsfrominvitroandinvivoex-
perimentalstudiessuggestingthatmanyenvironmentalchemicals
caninhibittheimmunesystemandalterhostresistancetoinfec-
tious agents ortumorcells [see reviewsby Lusteretal. (6) and
Deanand Murray (7)]. Additionalcredence isascribedtosuch
studies because the immune system oflaboratory animals, in-
cluding rodents, is remarkably similar to that ofhumans with
respecttoorganization, function,andresponsiveness. However,
therelevanceofthedoselevelsemployedinsomeofthesestudies,
comparedtolikelyhumanexposure,isofconsiderableconcern.
Immunotoxiccompoundsidentifiedfromsuchstudies, someof
whichhavebeenreportedtoproduceeffectsinhumans. include
certain halogenated aromatic hydrocarbons, organic solvents,
heavymetals,mycotoxins,oxidantgases,andabuseddrugs(i.e.,
alcohol, cocaine)(Table 1).
A study of particular interest, recently conducted through
Health and Welfare, Canada, indicatedthatmonkeyschronically
exposed to low levels ofa PCB mixture, representative ofthat
found intheenvironment, developimmunosuppressionprimari-
ly characterized by decreased CD4:CD8 ratios and antibody
responses (8). Furthermore, theseeffects wereselectiveforthe
immune systeminthatothertoxicities(e.g., liver, reproductive,
etc.) were notobserved. Amajorconcern wasthatimmunosup-
pression wasprevalentinoffspringexposedperinatally. Thatthe
developing immunesystemishighlysusceptibletochemical in-
jury hasbeensuggestedinanumberofexperimentalstudieswith
Table 1. Xenobiotics reportedto inhibit immune function
and decrease host resistance.a
Class Examples
Polyhalogenated aromatic hydrocarbons TCDD, PCB, PBB
Metals Lead, cadmium, arsenic
Aromatic hydrocarbons Benzene, toluene
Polycyclic aromatic hydrocarbons DMBA, BaP, MCA
Pesticides Trimethyl phosphorothioate
carbofuran, chlordane
Organotins Dibutyltin chloride
Aromatic amines Benzidine, acetylaminofluorene
Oxidant gases NO2, 03, SO2
Particulates Asbestos, silica, beryllium
Mycotoxins T-2, ochratoxin
Drugs Cyclosporin, methotrexate,
diphenylhydantoin
Abused drugs Cocaine, alcohol, marijuana
Abbreviations: TCDD, 2,3,7,8-tetrachlorodibenzo-p-dioxin; PCB, polychlor-
inated bipenyls; PBB, polybrominated biphenyls; DMBA, dimethylbenzan-
thracene; BaP, benzolajpyrene; MCA, methylcholanthrene; T-2, trichothecene
mycotoxin.
halogenated aromatic hydrocarbons, as reviewed by Vos and
Luster(9). Interestingly, thetypesofimmunological effects seen
in PCB-exposedprimates were similarto those reported to oc-
curin individuals fromTaiwanandJapan who wereexposed to
riceoilinadvertentlycontaminatedwithPCBsanddibenzofurans
(10). As a possible consequence ofthis immunosuppression,
someofthese individuals alsodeveloped increased incidences
ofsinopulmonary infections (1).
ImmunotoxicityofAIDSTherapeutics
Preclinical assessment of imune function is important for
manytherapeutics, and inparticularAIDStherapeutics, because
HIV-infected patients represent an already immunologically
compromised population. Recognizing this, the National In-
stitute ofHealth AIDS program has taken an active interest in
assessing the immunotoxicological effects ofa variety ofanti-
AIDSdrugs. Certainnucleosideanalogsarepotentinhibitorsof
HIV and have been usedwith some benefits in AIDS patients.
Thedose-limitinghematologicaltoxicitiesofnucleosideanalogs
include macrocytic anemia and granulocytopenia for 3 '-
azido-3'-deoxythymidine (AZT) (12) and neutropenia and
thrombocytopeniafor2'3'-dideoxycytidine(ddC) (13). Inrodent
studies it was reported that hematotoxicity could be detected
within5daysafterinitiationoftreatmentandwasreversibleafter
cessationoftreatment(14). Theseobservationscorrelatewithex-
perimentalstudiesshowingdrug-inducedinhibitionofbonemar-
rowprogenitorcellsafterin vitroorinvivoexposure(15,16). A
numberofnucleosideanalogsalsoproduceimmunotoxicityafter
in vivotreatmentinmice. Forexample. 2'3'-dideoxyadenosine
(ddA) and 2'3'-dideoxyinosine (ddl) have been shown to sup-
press the antibody plaque-forming cell response to sheep red
bloodcell immunization(17). In recentstudies, the nucleoside
analog, 2 3'-didehydro-2 3'-dideoxythymidine (d4T) produced
a pattern of myelotoxicity that was similar to AZT in that
erythroidprogenitors weremoresensitivetodrugtreatmentthan
myeloid progenitors (18). Similar hematotoxicities have been
observed in clinical trials with humans manifested by anemia
afteradministration ofd4T.
In addition to therapeutics that inhibit HIV replication, a
numberoftreatments arebeing used that target one or more of
theopportunisticinfectionsthatoccurinAIDSpatients. Penta-
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FIGURE 1. (A) Interleukin-l (IL-1) release frompentamidine-exposed macrophages as measured by thethymocyteco-culture assay. Dataare represented as mean
countsperminute ± SEofsupernatants derived fromquadruplicateculturesofalveolarmacrophages exposedtovehicleorpentamidine. (B) Northern blotanalysis
ofIL-la mRNA. Fordetermination ofIL-lamRNA levels, alveolar macrophages werepreincubated in mediawith orwithout 10MM pentamidineor 1 pM dex-
amethasone and subsequently stimulated for 3 hr with lipopolysaccharide (I pg/mL).
midine (4,4'-diaminodiphenoxy-pentane) isethionate, widely
used since the 1930s as an antiprotozoal agent, is often used
against AIDS-related Pneumocystis carinii pneumonia (PCP).
PCP is a frequent cause of morbidity and mortality in im-
munocompromised patients and afflicts more than 60% ofpa-
tients with AIDS. Although a high risk oftoxicity occurs with
parenteral administrationofpentamidine, administration viain-
halation has been successfully used for the treatment and pro-
phylaxis ofPCP inAIDSpatients (19). Theexactmechanismof
action for pentamidine on P carinii pneumonia is unclear,
although impairment ofoxidativephosphorylation, nucleicacid
synthesis, glucosemetabolism, anddihydrofolatereductasehave
all been suggested to contribute to itsefficacy.
Alveolar macrophages are the first immune cell to contact
aerosolized pentamidine. Considering the critical role of
macrophages inantimicrobial activity, wehavestudiedthe im-
munomodulatory effects of pentamidine on alveolar macro-
phagesandhavefoundthatthesecretionbutnotthetranscription
ofthe inflammatory cytokines, interleukin 1 (IL-1) and tumor
necrosis factor (TNF) (20), areinhibitedbypentamidineatphar-
macological doses(Fig. 1). Althoughtheprecisephysiologic role
forthesecytokines inthelowerlunghasnotbeenestablished, it
has been suggested thatreduced production ofthesemediators
contribute todefectivecellular responses, whileoverproduction
enhances local tissue damage. For instance, TNFdisplays an-
tiviral activity and a protective role in protozoan infections,
whereas it is implicated in inflammatory tissue destruction
and granuloma formation (21). Interestingly, alveolar
macrophages recovered from AIDS patients with PCP, but not
inAIDSpatientswithouttheinfection,exhibitmarkedly increas-
ed spontaneous production ofTNF. Thus, the efficacy ofpen-
tamidineagainstPCPmayinpartbemediatedbyitsabilitytoin-
hibit TNF release frombystandercells inthe lung.
Interferon-a (IFN-ca), anendogenousproteinwithantiviralac-
tivity, has also been used successfully in HIV-infected indi-
viduals. Theeffectiveness ofIFN-cx inAIDS appearstobedue
toitspleiotropiceffectsontargetcellsandprocesses integralto
thedisease. For example, although antiviral activity by IFN-ot
hasbeenobservedwhenusedaloneorinconjunctionwithAZT
(22), itisalsoeffectiveagainstthegrowthofKaposi's sarcoma,
acommonneoplasticdiseaseinAIDSpatients. Interferon-cx acts
directlyagainsttumorcellsaswellasindirectlythrough stimu-
lating NK cells. However, IFN-a also possesses immunotoxic
properties inthat it inhibits T- and B-lymphocyteproliferative
ability as well as stem cell differentiation in the bone marrow
(23).
Autoimmunity
Autoimmunediseasesarethoseinwhichanindividual'sown
immunesystemattacksoneormoretissuesororgans, resulting
infunctionalimpairment, inflammation, andsometimesperma-
nenttissuedamage. Usually thesediseasesareassociated with
thelossofimmunetolerancetoself-antigensanddemonstrable
immuneresponsestooneormoretissueantigens. Whennospe-
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cificantigencanbedetected, anautoimmuneprocess canbein-
ferred ifthere isinflammation ofatissueorgroupoftissuesthat
shownoevidenceofinfectionandiftheconditionrespondstoim-
munosuppressivetherapy. Anumberofenvironmentalchemicals
and therapeutic agents produce autoimmune responses, which
in some cases lead to autoimmune diseases in experimental
animalmodelsandhumans [reviewedbyKamulleretal. (24)and
Bigarzi (25)]. Developmentofautoimmunity isacomplexpro-
cessthatinvolves manyfactorsincludinggender(predominantly
females), genetic predisposition, physiological factors, anden-
vironmental factors. Thus, there is a need to establish notonly
theprevalenceofdirectchemical-inducedautoimmunity, butalso
whether chemical agents can contribute to the development of
autoimmune disease in humans.
Evidence fordrug-induced autoimmunity ismorecompelling
than environmentally related autoimmunity, as typified by re-
portsofpenicillamine- andprocainamide-inducedlupus. Auto-
immunity fromhydrazineoccurs inafairly restrictedpopulation
(i.e., slowacetylators). Thischemicalisfoundinvariousnatural
products includingtobacco, mushrooms, andalfalfaseeds. Other
drugs have been reported to produce autoimmune hemolytic
anemia or thrombocytopenia, the most notable being
methyldopa. Similar responses have also been reported in pa-
tients receiving chlorpropamide, procainamide, carbamazepine,
and interferon therapy [reviewed by Bigazzi (25)]. Other work
has focused on lymphoproliferative reactions induced by
diphenylhydantoin, thedevelopmentofthyroidantibodies inpa-
tientsreceivinglithium, anddrug-induced hepatitis inassocia-
tion with halothane, nitrofurantoin, or isoniazid treatment.
Evidenceofautoimmunity inducedbyenvironmentalchemicals,
particularly inhumans, islimited. Occupational orinadvertent
exposure to vinyl chloride and/or quartz has been linked to a
disorder resembling scleroderma. Thisdisorder, likeidiopathic
scleroderma, shows aprevalence forindividuals withtheHLA-
DR5haplotype. Certainmetals, suchasmercury, causeimmune-
complexglomerulonephritis inhumans(26), althoughtheextent
ofmercury-inducedautoimmunediseaseinhumansisunknown.
Itis well established thatlowlevelsofmercuryadministered to
susceptible strains ofmice and rats result in immune-complex
glomerulonephritis and nuclear autoantibodies. An autoim-
munlike disorder, referred to as toxicoil syndrome (TOS), has
alsobeenreported inalargepopulationofSpanishresidents who
inadvertentlyingestedaniline-adulteratedrapeseedoil(24). The
symptoms associated with TOS reveal similarities to those
observed in some humans receiving hydantoin-related com-
pounds.
Local Immunity in the Skin
Theskin isnotmerelyaninertbarrierthatphysicallyprevents
entry of foreign materials, but possesses biologically active
systems and products, including immunological systems, that
function as aneffectivedefense system. Theimmune systemof
the skin, called "skin-associated lymphoid tissue" (SALT) by
Streilein (27), contains multiple cell types that participate in
immune-mediated processes. These include Langerhans cells,
which possess antigen-presenting capabilities, anddendritic T-
cells, whichretainhelperandsuppressorfunction. Additional-
ly, immunecellsandactivecomponents (e.g., antibody-antigen
complexes) arereadilyrecruitedtotheskinfromthecirculatory
Material
Polycyclic aromatic hydrocarbons
Platinum salts
Cottondust
Formaldehyde
Grain and flour
Ethylenediamine, phthalic
and trimellitic
anhydride, toluene
diisocyanate
Phenylglycine acid chloride,
sulfone chloramides,
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Source
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Pharmaceutical
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Printers
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Meat wrappers
systemin responsetostimuliinitiatedattheskinsurface. Abun-
dantinthedermis arefibroblasts andcapillary endothelial cells
that bear cytokine receptors and can be induced to secrete
cytokines. Keratinocytes, which differentiate as they ascend
through theepidermis, are also reservoirs ofcytokines such as
inter leukin (IL)-1, which are secreted in response to various
stimuli (28). Becausetheskinis a commonsiteofexposure to en-
vironmental agents, itis notsurprising thatSALTis a common
target. Depending on thechemical agent and thedose, toxicity
canbemanifested aseithercontacthypersensitivity, inflamma-
tion, or immunosuppression.
Contacthypersensitivity reactions inthe skin are common, af-
fecting literally millions ofAmericans. The incidenceassociated
with environmental oroccupational exposure is unknown, but
hasbeenestimated tobeapproximately 5-10% ofall cases. The
events associated with induction and elicitation of chemical-
induced hypersensitivity reaction have been intensely inves-
tigated. ItisthoughtthatLangerhans cellsinitially interactwith
antigen intheskin and transport itto thedraining lymph nodes
where the antigen is presented to immunocompetent T-lym-
phocytes in context withclass II antigens. This initiates an im-
mune responsewhereby subsequent exposuretotheantigen can
evokeelicitation in sensitized individuals. This involves the in-
teractionofprocessedantigenwith sensitized lymphocytes. The
sensitized lymphocytes are transformed into lymphoblasts,
whichproliferateandsecretevariousbiologicallyactiveproducts
including antibodies (e.g., IgE) and lymphokines. These pro-
ducts, eitherdirectly orindirectly, areresponsible forthe genera-
tionofinflammatory mediators such aschemoattractants, adhe-
sion molecules, andpharmacological mediators.
Anumberofchemicalagentshavethecapacity toproduce con-
tacthypersensitivity, awidelyrecognizedenvironmental and oc-
cupational problem [reviewedby Menne (29)]. Apartial listof
compounds known orpresumed toproduceallergic responses is
shownin Table2. Thecharacteristic that setsallergic responses
apartfromimmunemechanisms involved inhostdefense is that
the reaction is excessive and often leads to tissue damage.
Chemical-induced hypersensitivities fall into two categories
distinguished notonly mechanistically buttemporally: delayed-
typehypersensitivity, acell-mediated responsethatoccurswithin
24-48hrafterchallenge, andimmediatehypersensitivity, which
Table2. Industrial materials known or presumed
tocauseallergic problems.
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ismediatedbyimmunoglobin, mostcommonlyIgE, and mani-
festswithinminutesafterexposuretoanallergen. Thetypeofim-
mediate hypersensitivity response elicited (i.e., anaphylatic,
cytotoxic, Arthusorimmunecomplex)dependsontheinteraction
ofthesensitizingantigenorstructurally relatedcompoundwith
antibody. Incontrast, delayed-typehypersensitivity responsesare
characterizedbyT-lymphocytes, bearingantigen-specificrecep-
tors, which, oncontactwithcell-associatedantigen, respondby
secretingcytokines. Metalssuchasberyllium, mercury, cobalt,
nickel, platinum, chromium, andgoldcaninduceaspectrumof
hypersensitivity responses, from delayed-onset to immediate.
Nickel is considered a medium-to- strong contact sensitizer in
humansandhasbeenusedasa "gold standard" indevelopment
ofnew assaysforassessinghypersensitivity.
In addition to contact hypersensitivity responses, some
chemicals and environmental agents can alter the normal pro-
cesses associated with SALT and in certain instances suppress
systemic immunity in laboratory animals. Inthe former, forex-
ample, thedisappearanceor functional loss ofLangerhans cells
isassociatedwith dermalexposure toultraviolet light, particular-
ly UV-B radiation (30), or certain chemical agents such as
dimethylbenzanthracene (31), lanthanides (32), pentamidine
(33), or phorbol esters (34). Subsequently, the ability to elicit
contacthypersensitivity with known sensitizers is lostwhen the
skin is pretreated with these agents. On the other hand, some
compounds, such as thosewith antioxidant activity, exacerbate
contact hypersensitivity in mice afterdermal exposure. This is
associated with an increase in Langerhans cell function as
evidenced by increases inIa antigen density on the cell surface
(35). Systemic immunosuppression may occur in experimental
animals atdosesofUV-Bhigherthanthatwhich suppresses local
immunity (36). This is characterized by an inability to respond
to sensitizers when applied to unirradiated as well as irradiated
sites and a decrease in delayed hypersensitivity responses. The
mechanism(s) responsible for these effects are unclear, but may
depend on the induction of antigen-specific suppressor T-
lymphocytes andbioactiveproducts released from UV-damaged
keratinocytes. An association between skin cancers and im-
munosuppression by UV-B has been established in laboratory
animals where UV-induced immunosuppression affects the re-
jectionofUV-induced skin tumors (37). UV-B radiationmay also
affect SALT inhumans, as suggested by theobservation that UV
exposure inhibited the subsequent ability to induce contact
hypersensitivity at the irradiated site in 40% ofnormal subjects
and in 90% ofpatients with sunlight-induced skin cancer (38).
Chemical agents may also produce local inflammatory
responses in the skin through nonspecific mechanisms. The
keratinocyte, which represents the vast majority of cells that
compose the epidermis (> 95%), is the primary source of
immuno-activecytokines. Ithas been postulated thatthe release
of these mediators in response to various stimuli orchestrate
many ofthe immunological and inflammatory responses thatoc-
cur in the skin after exposure to dermatotoxins (39). In this
respect, the pathogenesis of psoriasis, a chronic skin disease
characterized by excessive keratinocyte proliferation and inflam-
matory cell infiltrates in psoriatic plaques, is closely associated
with altered regulation ofkeratinocyte-produced cytokines (40)
and may servetocharacterizechemical-induced dermatotoxicity.
Themechanisms and events by whichthese processes occurare
currently majorareas ofresearch. Cytokinesknownorpresumed
tobeproductsofkeratinocytes includeIL-lca and(3, 1L-3, IL-6,
IL-8, granulocytic macrophagecolony-stimulatingfactor, tumor
growth factor-ca and(3, andTNF-a. Baseduponseverallinesof
invitroandinvivoevidence,acytokinenetworktheoryhasbeen
proposed (39). Inthistheory, environmental stimuli, whichin-
cludescontactallergens,ultravioletlight,orcertaindermatotoxic
chemicals, canactdirectlyonkeratinocytes, resultinginthe re-
leaseofIL-1 andTNF-ca, aswellastheexpressionofICAM-1, an
adhesionligandforlymphocytes. ThesecretionofIL-1 andTNF-
a leadstotheexpressionofsurfaceleukocyteadhesionmolecules
(e.g.,VCAM-1)aswellasthereleaseofkeratinocyte-derivedIL-8,
a potent attractant for T-lymphocytes and polymorphonuclear
leukocytes. Tumornecrosisfactor-axand/orIL-1 mayalso stim-
ulatekeratinocytes inanautocrinefashion. Whentheinitial en-
vironmentalstimulantisantigenic, suchasinthecasewithNIS04,
theresponseinvolvesincreasedappositionofmononuclearcells
with subsequent involvement of sensitized T-cells, which in-
creasestheintensity andperpetuationofthe response.
Local Immunity in the Lung
The lung represents one ofthe principal portals ofentry for
many chemical agents. Todeal with the influx ofsuch foreign
material, the lung has evolved a complex immunological
frameworkofcellsandmediators. Inhaledmicrobesorantigens
maybephagocytized intheconductingairwaysbymacrophages
or may be processed for subsequent presentation by dendritic
cells. The lung also contains significant lymphoid tissue in the
form oflymph nodes positioned in the mediastinum and hilar
areasofthelungsaswellasinterstitially inparenchymal tissue.
Additionally, theluminal surface secretions contain significant
amounts ofimmunoglobulin, whichispredominantly oftheIgA
class.
Lung immunity canbeatargetofairborne chemicals as well
asfunctionasapulmonarydefensemechanismagainstchemical-
inducedcell injury. Becauseoftheir strategic locationwithinthe
lung, alveolar macrophages provide theinitialdefense systemfor
the body against inhaled toxicants, and numerous compounds
have been shown to modulate its activity (4I). Additional im-
munologic defenses operating in the lung includehumoral im-
munity and cell-mediated immunity derived from bronchial-
associated lymphoid tissueaswell as aninterstitial lymphocyte
compartment within lung tissue. Inparticular, lung-associated
NKactivityhasbeenshowntobeeitherup-ordownregulatedby
a number ofagents including IFN-a (42) and phosgene (43).
Overall suppression ofsuch systems canpredispose the host to
infectious agents ortumordevelopment, ashasbeenshowntooc-
cur for pollutant gases such as ozone, aphotochemical oxidant
resulting from atmospheric reactions of hydrocarbons and
nitrogen oxides catalyzedby sunlight. Inexperimental animals,
ozonedecreases pulmonary resistancetobacterialchallenge in-
cluding Streptococcus sp., Pasteurellahaemolytica, andMyco-
bacterium tuberculosis (44). This increased susceptibility may
relateto impairmentofalveolarmacrophage functions, although
recent studies have suggested that T- and B-cell functions may
also be impaired after ozone inhalation. Inhalation ofasbestos
modulates pulmonary and systemic immunity. Asbestos ex-
posure in humans is also associated with respiratory diseases in-
cluding asbestosis, fibrosis, malignantmesothelioma, and bron-
chogenic carcinoma. Alterations in cellular and humoral
223224 LUSTERANDROSENTIAL
immune responses often accompany these conditions. Im-
pairments incell-mediated immunity in humansby asbestos is
characterizedbydecreases indelayedhypersensitivity responses,
the numbers ofcirculating T cells, and T-cell proliferation. In
contrast, patients with asbestosis present hyperactive T-cell
responses, often manifested by increased levels of serum im-
munoglobulins and secretory IgA.
Acute hypersensitivity disease or pulmonary allergic re-
sponses represent one of the major sources of immunotox-
icological complaints. Pulmonary hypersensitivity, allergic
alveolitis, and asthma are syndromes with very complex etio-
logicbackgrounds. Itisestimatedthatmorethan 10millionper-
sons in the United States suffer from asthma. In the general
population, asthmaprevalence rates increased 29% from 1980
to 1987, and, during the same time period, asthma-associated
mortality increased 31% (2891 mortalities in 1980versus 4360
in 1987) (45). Asthma ischaracterized by airway hyperrespon-
siveness, which can be manifested by an exaggerated bron-
choconstriction response to many physical changes (e.g., cold
air) as well aschemical andpharmacological agents. Although
numerous factors may airway contribute to the development of
hyperesponsiveness, clinical and experimental evidence sug-
gests, that altered lung immunity is a major factor. Mor-
phological studies have shown thatbronchial infiltration ofin-
flammatory cells occurs in severe disease as well as mild
episodes. Similarly, there is evidence to suggest that altered
cellular responses and increased levels of inflammatory me-
diators are associated with asthma and airway hypersrespon-
siveness. While there appears tobeagenetic component tothe
pathogenesis ofasthma, numerous environmental factors may
alsobeinvolved, including allergens, cigarettesmoke, andviral
agents. Airbornepollutants, includingozonesulfurdioxide, and
nitricoxide, havealsobeencitedtocontributetothepathogenesis
orexacerbation ofasthma. A numberofstudies have shown an
associationbetweenambientconcentrations ofthesepollutants
and increased hospital admissions for asthma or increased
asthma symptoms (46). However, the immunological changes
produced by these compounds that predispose the host to
pulmonary hypersensitivity remains to be determined.
In addition to environmental exposure, occupational factors
arethought tocontributeto2% ofallasthma cases. Trimellitic
anhydride, which reacts as ahapten, aswell aschromium, acid
anhydrides, ethanolamines, complexamines, andplicatic acid,
areall industrial productscapableofinducingasthmaticcondi-
tions or sequela in humans (Table 2). One ofthe most studied
chemicals regarding itspotential toinduce lunghypersensitivi-
ty istoluenediisocyanate (TDI), aclassicalrepresentativeofthe
isocyanate compounds used intheproductionofplastics. Inin-
dustrialworkers, TDIexposurecancauseasthma(5-10% ofall
exposed workers) aswellascontactdermatitis. Characteristics
ofTDI, sharedby many chemical agents that inducehypersen-
sitivity, arealowmolecularweight(500-1000)andhighreactivi-
ty to macromolecules, particularly proteins. Studies in guinea
pigsdemonstrated thatathreshold concentration isrequired for
pulmonary sensitization.
Beryllium, ametal used inthemanufactureofavarietyofin-
dustrial components, haslongbeenassociated withpulmonary
hypersensitivity including acute pneumonitis and chronic
pulmonary granulomatous disease (berylliosis) (47). The rela-
tionship between beryllium exposure and induction of cell-
mediated immunity is well established with T lymphocyte
blastogenesis in the presence ofberyllium, serving as a diag-
nostic tool forberylliosis.
Conclusions and Future Direction
The immune system iscomposed ofseveral cellpopulations
whose maturation is subject to orderly control by endogenous
hormones and/orexogenousbacterial products. Thesemediators
possessactivation, growthpromotion, ordifferentiationproper-
ties and are under the influence of potent and well-defined
regulators. From studies inrodents andlimitedobservations in
humans, it is apparent that a number of environmental and
chemical agents can adversely affect the immune systems,
resulting in either immunosuppression, hypersensitivity, or
autoimmunedisease. Theseexamplesandourcurrentknowledge
about the pathogenesis ofdisease support the possibility that
chemical-induced damage to the immune system may be
associatedwithawidespectrumofdiversepathological condi-
tions, some ofwhich may become detectable only after a long
latency. Likewise, exposure to chemical agents mightrepresent
an additional risk to individuals with already fragile immune
systems (e.g., malnutrition, infancy, old age).
Thevalueofincorporating immunological experimental data
for the toxicological assessment of drugs, chemicals, and
biologicals forhumanriskassessmenthasbeen increasingly ac-
cepted. Forexample, in addition to previously established test
guidelines proposed by the Environmental Protection Agency
(EPA) forhypersensitivitytesting, theEPA(48)andtheFoodand
DrugAdministration (49)haverecentlydiscussedthebenefitsof
testing the immunosuppressive potential of biochemical pest
control agents and antiviral drugs, respectively. Furthermore,
EPA has established reference doses (Rfor NOAEL/SF) using
immunotoxicity data for several compounds including 1,1,2-
trichloroethane, 2,4-dichlorophenol, and dibutyltinoxide, and
theAgency forTopic SubstancesandDiseaseRegistry hasderiv-
ed, "minimum risk levels" for arsenic, dieldrin, nickel,
1,2-dichloroethane, and2,4-dichlorophenol fromimmuneend-
points (M. Selgrade, personal communication). Thepreceding
decadeofresearchhasprovided adatabase ofimmunotoxic and
nonimmunotoxic compounds, a better understanding of the
mechanisms responsible for hypersensitivity disease, studies
correlating immunedysfunction andalteredhostresistance, and
more predictive methods for detecting immunomodulatory
chemicals. Future research is needed to a) further refine and
validate immune functiontests andhost resistance assays, par-
ticularly intherataswellastests forautoimmunity; b) establish
better test methods toevaluatetheeffectsofchemical exposure
on lung and skin immunity; c) develop and evaluate in vitro
methodology fordetectingchemical-induced immunotoxicity;
d) developand implementatestingbattery toexamine immune
changes inhumansoccupationally orenvironmentallyexposed
to chemicals shown to be immunotoxic in laboratory animals;
ande)establishappropriatemathematical models toallowforex-
trapolating experimental studies.
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